These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 33672884)

  • 21. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
    Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
    Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity.
    Kawasumi M; Bradner JE; Tolliday N; Thibodeau R; Sloan H; Brummond KM; Nghiem P
    Cancer Res; 2014 Dec; 74(24):7534-45. PubMed ID: 25336189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive complex systems approach to the study and analysis of mammalian cell cycle control system in the presence of DNA damage stress.
    Abroudi A; Samarasinghe S; Kulasiri D
    J Theor Biol; 2017 Sep; 429():204-228. PubMed ID: 28647496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Cell Cycle Checkpoint Kinases to Overcome Intrinsic Radioresistance in Brain Tumor Cells.
    Vlatkovic T; Veldwijk MR; Giordano FA; Herskind C
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitors of cell cycle checkpoint target Wee1 kinase - a patent review (2003-2022).
    Yan J; Zhuang L; Wang Y; Jiang Y; Tu Z; Dong C; Chen Y; Zhu Y
    Expert Opin Ther Pat; 2022 Dec; 32(12):1217-1244. PubMed ID: 36620912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition.
    Guertin AD; Martin MM; Roberts B; Hurd M; Qu X; Miselis NR; Liu Y; Li J; Feldman I; Benita Y; Bloecher A; Toniatti C; Shumway SD
    Cancer Cell Int; 2012 Nov; 12(1):45. PubMed ID: 23148684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
    Li S; Wang L; Wang Y; Zhang C; Hong Z; Han Z
    J Hematol Oncol; 2022 Oct; 15(1):147. PubMed ID: 36253861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
    Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
    Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses.
    Yan T; Desai AB; Jacobberger JW; Sramkoski RM; Loh T; Kinsella TJ
    Mol Cancer Ther; 2004 Sep; 3(9):1147-57. PubMed ID: 15367709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. G2 checkpoint abrogators as anticancer drugs.
    Kawabe T
    Mol Cancer Ther; 2004 Apr; 3(4):513-9. PubMed ID: 15078995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia.
    Ghelli Luserna Di Rorà A; Bocconcelli M; Ferrari A; Terragna C; Bruno S; Imbrogno E; Beeharry N; Robustelli V; Ghetti M; Napolitano R; Chirumbolo G; Marconi G; Papayannidis C; Paolini S; Sartor C; Simonetti G; Yen TJ; Martinelli G
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31717700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. UV-induced G2 checkpoint depends on p38 MAPK and minimal activation of ATR-Chk1 pathway.
    Warmerdam DO; Brinkman EK; Marteijn JA; Medema RH; Kanaar R; Smits VA
    J Cell Sci; 2013 May; 126(Pt 9):1923-30. PubMed ID: 23447674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs.
    Toledo LI; Murga M; Fernandez-Capetillo O
    Mol Oncol; 2011 Aug; 5(4):368-73. PubMed ID: 21820372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma.
    Barnaba N; LaRocque JR
    Cell Cycle; 2021 Jun; 20(11):1041-1051. PubMed ID: 33966611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. G2/M Checkpoint Abrogation With Selective Inhibitors Results in Increased Chromatid Breaks and Radiosensitization of 82-6 hTERT and RPE Human Cells.
    Nikolakopoulou A; Soni A; Habibi M; Karaiskos P; Pantelias G; Terzoudi GI; Iliakis G
    Front Public Health; 2021; 9():675095. PubMed ID: 34123995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
    Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
    Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olaparib-Resistant
    Biegała Ł; Gajek A; Marczak A; Rogalska A
    Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability.
    Chen Y; Poon RY
    Front Biosci; 2008 May; 13():5016-29. PubMed ID: 18508566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
    Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
    Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.
    Bucher N; Britten CD
    Br J Cancer; 2008 Feb; 98(3):523-8. PubMed ID: 18231106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.